Effects of Shikonin on the Functions of Myeloid Dendritic Cells in a Mouse Model of Severe Aplastic Anemia
Open Access
- 20 February 2020
- journal article
- research article
- Published by Wiley in Mediators of Inflammation
- Vol. 2020, 1-10
Abstract
This study is aimed at investigating the effects of shikonin, a pyruvate kinase M2 (PKM2) inhibitor, on the functions of myeloid dendritic cells (mDCs) in a mouse model of severe aplastic anemia (AA) generated by total body irradiation and lymphocyte infusion. Flow cytometry and qPCR were used to determine the proportions of PKM2+ mDCs and other immune indicators in the AA mice. Glucose consumption level, pyruvate generation level, and ATP content were used to determine the level of glycolytic metabolism in the mDCs. The survival rates of AA mice were evaluated after the administration of shikonin or the immunosuppressive agent cyclosporin A. The AA mice displayed pancytopenia, decreased CD4+/CD8+ cell ratio, increased perforin and granzyme levels in CD8+ cells, increased costimulatory CD80 and CD86 expressions, and inadequate regulatory T cell number. In vivo animal experiments showed that the shikonin-mediated inhibition of the PKM2 expression in mice was associated with high survival rates. In addition, the administration of cyclosporin A or shikonin decreased the expression of cytotoxic molecules and costimulatory CD80 and CD86 on CD8+ cells. Taken together, the results of this study indicated that shikonin could inhibit the activation and proliferation of mDCs as well as the activation of downstream cytotoxic T cells by reducing the PKM2 level in mDCs.Keywords
Funding Information
- Tianjin Science and Technology support key project plan (20140109, 12JCZDJC21500, 15JCYBJC24300, 14JCYBJC25400, 81400088, 81400085, 81570111, 81570106)
- Tianjin Municipal Natural Science Foundation (20140109, 12JCZDJC21500, 15JCYBJC24300, 14JCYBJC25400, 81400088, 81400085, 81570111, 81570106)
- Tianjin Municipal Natural Science Foundation (20140109, 12JCZDJC21500, 15JCYBJC24300, 14JCYBJC25400, 81400088, 81400085, 81570111, 81570106)
- Tianjin Municipal Natural Science Foundation (20140109, 12JCZDJC21500, 15JCYBJC24300, 14JCYBJC25400, 81400088, 81400085, 81570111, 81570106)
- National Natural Science Foundation of China (20140109, 12JCZDJC21500, 15JCYBJC24300, 14JCYBJC25400, 81400088, 81400085, 81570111, 81570106)
- National Natural Science Foundation of China (20140109, 12JCZDJC21500, 15JCYBJC24300, 14JCYBJC25400, 81400088, 81400085, 81570111, 81570106)
- National Natural Science Foundation of China (20140109, 12JCZDJC21500, 15JCYBJC24300, 14JCYBJC25400, 81400088, 81400085, 81570111, 81570106)
- National Natural Science Foundation of China (20140109, 12JCZDJC21500, 15JCYBJC24300, 14JCYBJC25400, 81400088, 81400085, 81570111, 81570106)
This publication has 23 references indexed in Scilit:
- Regulatory T cells and CD20+B cells in pediatric very severe aplastic anemia: possible clinical markers for evaluating the therapeutic efficacy and prognosisHematology, 2018
- Shikonin exerts antitumor activity in Burkitt’s lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicinScientific Reports, 2018
- PKM2 Is Required to Activate Myeloid Dendritic Cells from Patients with Severe Aplastic AnemiaOxidative Medicine and Cellular Longevity, 2018
- Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinaseEuropean Journal of Medicinal Chemistry, 2017
- CXCR4 expression on pathogenic T cells facilitates their bone marrow infiltration in a mouse model of aplastic anemiaBlood, 2015
- Differential expression of the proteome of myeloid dendritic cells in severe aplastic anemiaCellular Immunology, 2013
- Cancer metabolism meets systems biology: Pyruvate kinase isoform PKM2 is a metabolic master regulatorJournal of Carcinogenesis, 2013
- PKM2 inhibitor shikonin suppresses TPA‐induced mitochondrial malfunction and proliferation of skin epidermal JB6 cellsMolecular Carcinogenesis, 2012
- Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2Oncogene, 2011
- Antigen Presentation by Dendritic Cells in Tumors Is Disrupted by Altered Metabolism that Involves Pyruvate Kinase M2 and Its Interaction with SOCS3Cancer Research, 2010